Florida Doctor Awarded $1.5 Million Against OptumRx in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Florida Doctor Awarded $1.5 Million Against OptumRx in Landmark Defamation Case

TAMPA, Fla., Dec. 01, 2016 (GLOBE NEWSWIRE) -- After a week-long arbitration before a panel of three arbitrators, a local physician received a $1,500,000.00 award against healthcare giant OptumRx, a pharmacy benefits management company associated with United Healthcare.  The award, which also required OptumRx to pay all costs associated with the litigation, included a finding that family medicine physician Jose I. Lopez, M.D. was entitled to punitive damages in the amount of $1,000,000.00 due to OptumRx’s “intentional misconduct or gross negligence” that was “condoned, ratified or consented to” by Optum’s officers, directors or managers. 

Dr. Lopez was represented by Jody M. Valdes and Paul M. Weekley of Weekley Schulte Valdes in Tampa. 

“More strikingly, however, the Panel of Arbitrators determined that OptumRx, Inc.’s wrongful conduct was ‘motivated solely by unreasonable financial gain and the unreasonably dangerous nature of the conduct, together with the high likelihood of injury resulting from the conduct, was actually known by the managing agent, director, officer, or other person responsible for making policy decisions,’” said Valdes.

“The case arose after OptumRx publicly and repeatedly made false statements about Dr. Lopez, wrongly labeling him as a physician-sanctioned by the Office of Inspector General.  In actuality, OptumRx had misidentified Dr. Lopez.  The Jose Lopez who was sanctioned by OIG lived in another city in Florida and was not even a physician.  The Panel of Arbitrators concluded that OptumRx injured Dr. Lopez’s reputation in the community by falsely advising pharmacies, Dr. Lopez’s patients, and others that Dr. Lopez was a sanctioned provider.  OptumRx failed to acknowledge the mistake and continued making the false statements despite repeated attempts by Dr. Lopez to get OptumRx to investigate whether OptumRx had identified another person with a similar name,” stated Weekley.

“We believe that this is the first case of its kind, in which a pharmacy benefits manager has been held accountable for poor procedures that resulted in a physician being wrongfully defamed,” stated Valdes.  “During the litigation process, we learned that Dr. Lopez was one of many physicians who was defamed by similar misconduct or gross negligence,” added Weekley.

The Panel concluded that the “clear and unmistakable import of the false statements was that Claimants had engaged in some improper conduct sufficient to merit a “penalty, punitive or disciplinary action,” which is a definition of 'sanctioned',” said Valdes.

The Panel further noted that the “statements conveyed the false notion that Claimants had committed some offense in the medical profession sufficient to be disciplined and excluded as a Medicare provider – only leaving to the audience’s imagination which bad act, whether it be fraud, malpractice, etc., led to the punishment.”  In reality, Dr. Lopez has always been in good standing with the state licensing agency, and with Medicare,” stated Weekley.

“The Panel determined that the evidence established to a clear and convincing standard that OptumRx, Inc. was aware of a problem with physicians being improperly listed as “sanctioned” and was specifically aware of this problem with Dr. Lopez. However, OptumRx, Inc. was unwilling to “take the few hours necessary to correct the information before publishing the information and did not engage in any efforts to correct its…continual misidentification,” said Valdes.

Dr. Lopez was pleased with the decision and commented that “this case was not about money.  This case about sending a strong and clear message that faceless companies that libel and slander doctors must be held accountable for their actions.”   

Eric W. Rose with Englander Knabe & Allen testified as an expert witness and addressed the effects of disseminating the false information and the impact on the doctor’s professional reputation.  Rose also testified about the appropriate standard of care that should have taken place and outlined steps Dr. Lopez should take to recover his good professional reputation.

Contact: Paul M. Weekley, Esquire (813) 221-1154 or pweekley@wsvlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 49

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 273

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 79

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 290

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 133

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 189

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 103

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 21

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 675

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 188

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring AI's Impact on CRM Visibility and Brand Trust

Updated Category News Views 217

Understanding the Role of AI in CRM Visibility Brandi AI has recently launched its AI Visibility Index series, which offers insightful measurements of how industries are perceived in AI-generated responses. This new series highlights the ways in which customer relationship management (CRM) brands are represented through the lens of advanced AI answer engines. The AI...

Continue Reading
Celldex Therapeutics Thrives Amid Developments with Briquilimab

Updated Category News Views 148

Overview of Celldex Therapeutics and Briquilimab Celldex Therapeutics (NASDAQ: CLDX) is navigating an exciting phase as it explores treatments for chronic conditions like Chronic Inducible Urticaria (CIndU). Analysts have closely observed the efficacy of briquilimab, highlighting its performance through recent studies. Analyst Insights on Celldex and Briquilimab Goldman...

Continue Reading
XPENG's Financial Success in Q3 2024: Key Insights Revealed

Updated Category News Views 238

XPENG's Journey in the Third Quarter of 2024 XPeng Inc. (“XPENG” or “the Company,” NYSE: XPEV and HKEX: 9868) recently disclosed its financial results for the third quarter ended September 30, 2024. This marks a significant period showcasing growth in revenues and vehicle deliveries, reflecting the company's robust strategy in the smart electric vehicle market....

Continue Reading
Apple Inc. Beats Earnings Expectations: Analysts React

Updated Category News Views 144

Apple Inc. Overcomes Challenges with Strong Quarterly Results Apple Inc.‘s latest quarterly performance has generated significant buzz in the tech world. Analysts reveal that the results showcase a resilient company navigating through various market challenges. This performance not only reflects strong sales of products like the iPhone but also highlights impressive...

Continue Reading
Class Action Alert: Investors Have Rights with AMMO, Inc.

Updated Category News Views 237

Class Action Lawsuit Against AMMO, Inc. In a proactive move for investors, Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against AMMO, Inc. (NASDAQ: POWW). This suit comes in light of significant losses experienced by investors in the company due to alleged misstatements and omissions regarding its business practices. Understanding the Class...

Continue Reading